The PennZone

  • Home
  • Business
  • Health
  • Non-profit
  • Technology
  • Services
  • Financial
  • Travel
  • Construction

Utah attempts to legalize placenta cell therapy
The PennZone/10266985

Trending...
  • Melospeech Inc. Accepts Nomination for HealthTech Startup of the Year
  • KIKO NATION TOKEN (Official Release)
  • SIMM Capital Fund Surpasses $25M Raised and $100M+ in Real Estate Assets
Parent's Guide to Cord Blood Foundation
Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

BROOKEVILLE, Md. - PennZone -- Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

Parent's Guide to Cord Blood Foundation is a small non-profit in the biotech space. We are the first to break the story that the Utah state legislature did not realize what they were voting for when they passed Utah S.B. 199.

More on The PennZone
  • BPM Systems Launches New Automated Packaging & Labeling Solution for Manufacturers Across The US
  • EnergyStrat Launches Global LNG Risk Outlook 2025–2030
  • Strong Revenue Gains, Accelerating Growth, Strategic Hospital Expansion & Uplisting Advancements: Cardiff Lexington Corporation (Stock Symbol: CDIX)
  • Holiday Decorations Most Likely to Cause Injuries
  • UK Financial Ltd Confirms Official Corporate Structure of the Maya Preferred Project and Its Dual-Class Token System

The FDA still considers unapproved stem cell therapies to be illegal, and when it comes to drug regulations, federal law takes supremacy. This is not the same as states ignoring federal law and legalizing recreational drugs. In the case of stem cell therapy, patients that receive unregulated products with insufficient oversight could suffer serious adverse events. The new law Utah S.B. 199 is going to trigger a showdown between the federal government and Utah. Doctors who administer therapy to patients under the new Utah law could be sued by the Dept. of Justice. At a bare minimum, we are calling for the state of Utah to establish oversight of this arena before patients are hurt.

Contact
Frances Verter, PhD
***@parentsguidecordblood.org


Source: Parent's Guide to Cord Blood Foundation

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Twin Flame Visions Announces Surge in Traffic and Engagement Following Breakout Ad Performance
  • FreeTo.Chat - The bold, Anonymous Confession Platform, ushers in a new era of tension relief
  • Hyatt House Fresno Celebrates Grand Opening, Introducing the First Hyatt House in Fresno, California
  • "I Make Music Not Excuses" Journal by Anthony Clint Jr. Becomes International Amazon Best Seller, Empowering Music Creators Worldwide
  • Megan Markovci Honored as One of Top Young Travel Agents in the Industry
  • DanReDev, Kaufman Development & Oldivai Announce Major 2026 Projects Nationwide
  • Twin Flame Visions Disrupts the Industry With Record Ad Performance and Rapid User Growth
  • Accelerating Precious Metals Expansion and Digital Asset Innovation Ahead of 2026: Asia Broadband Inc. (Stock Symbol: AABB)
  • SIMM Capital Fund Surpasses $25M Raised and $100M+ in Real Estate Assets
  • Naturism Resurgence (NRE) Announces the World's First Standardised Stigma Measure (SSM) for Naturism
  • London Art Exchange Emerges as a Leading Force in UK Contemporary Art, Elevating Three Artists to Secondary-Market Success
  • God's Meal Barrel Combats the Increased Community Need in 2025
  • myLAB Box Expands, Becoming the First and Only At-Home Testing Company to Serve the Entire Family—Human and Furry—with New Pet Intolerance Test
  • Entering 2026 with Expanding Footprint, Strong Industry Tailwinds, and Anticipated Q3 Results: Off The Hook YS Inc. (N Y S E American: OTH)
  • Philadelphia Startup NoPlex Creates an ADHD/Neurodiversity-Focused Alternative to Productivity Apps
  • Tiger-Rock Martial Arts Appoints Jami Bond as Vice President of Growth
  • Super League (N A S D A Q: SLE) Enters Breakout Phase: New Partnerships, Zero Debt & $20 Million Growth Capital Position Company for 2026 Acceleration
  • Finland's Gambling Reform Promises "Single-Click" Block for All Licensed Sites
  • Private Keys Are a Single Point of Failure: Security Advisor Gideon Cohen Warns MPC Technology Is Now the Only Defense for Institutional Custody
  • Compliance Is the Ticket to Entry: Legal Advisor Gabriela Moraes Analyzes RWA Securitization Paths Under Brazil's New Legislation

Popular on PennZone

  • Liquidity Aggregation: US-Registered JHKXWL Integrates AI Analytics for Brazilian and Global Institutional Traders - 710
  • BumblebeeSmart Introduces Rounded Busy Board Set for Preschoolers - 229
  • Light Her Way Launches New Cohort of Board of AdviseHERS to Prepare Women for Board-Ready Leadership - 110
  • Corcoran DeRonja Real Estate Welcomes Siobhán Simões to Its Growing Team
  • Heritage At Manalapan - A New Luxury Single Family Home Community Coming Late 2025
  • Turbo vs. Experts: Tracking OddsTrader's AI Performance at the NFL's Midpoint
  • Dispelling Holiday Suicide Myth: CDC Data Shows Suicide Rates Lowest in December; International Survivors of Suicide Day Emphasizes Need for Action
  • The Lashe® Announces Exclusive November Savings for Lash and Beauty Professionals
  • November is Lung Cancer Awareness Month: Screening Saves Aims to Increase Access to Lung Screenings in NC
  • Cut Costs & Boost Profits with the First Major Upgrade in 30 YEARS Replacing Rotary Lasers and Historic Clear Tube Altimeter Bubbles

Similar on PennZone

  • High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
  • OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
  • FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
  • Revenue Expansion, Regulatory Momentum, and a Leadership Position in the $750 Million Suicidal Depression: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • $750 Million Market on Track to $3.35 Billion by 2034: $NRXP Launches First-in-Florida "One Day" Depression Treatment in Partnership with Ampa Health
  • $750 Million Market Set to Soar to $3.35 Billion by 2034 as Florida Launches First-in-Nation One-Day: NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP
  • U.S. Entrepreneur Anjo De Heus Builds Innovation Bridge Between America and the Gulf
  • Global Innovators Take the Stage at the WorldUpstart Accelerator Showcase in Philadelphia
  • Phinge's Netverse to Redefine Clinical Trial Safety and Data Integrity with Netverse Patented, Hardware-Verified Platform
  • MDRN MUSE Expands Insurance Network Coverage to Include Delta Dental & Cigna
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us